Esperion Therapeutics (NASDAQ:ESPR) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Esperion Therapeutics (NASDAQ:ESPR) announced its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.10) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.06), FiscalAI reports. The firm had revenue of $80.10 million during the quarter, compared to analyst estimates of $84.52 million.

Esperion Therapeutics Price Performance

Esperion Therapeutics stock remained flat at $3.14 during mid-day trading on Friday. 7,427,546 shares of the company’s stock traded hands, compared to its average volume of 8,629,511. The firm has a market capitalization of $808.25 million, a PE ratio of -18.47, a P/E/G ratio of 2.56 and a beta of 0.91. Esperion Therapeutics has a 12-month low of $0.69 and a 12-month high of $4.18. The firm’s fifty day simple moving average is $2.53 and its two-hundred day simple moving average is $3.09.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth $35,000. Captrust Financial Advisors acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth $40,000. Cibc World Markets Corp acquired a new stake in shares of Esperion Therapeutics during the fourth quarter worth $57,000. Hudson Bay Capital Management LP purchased a new stake in shares of Esperion Therapeutics in the 4th quarter valued at approximately $67,000. Finally, Hsbc Holdings PLC purchased a new stake in shares of Esperion Therapeutics in the 4th quarter valued at approximately $70,000. 47.39% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the stock. Jefferies Financial Group lowered shares of Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Esperion Therapeutics in a research report on Tuesday, April 21st. HC Wainwright cut Esperion Therapeutics from a “buy” rating to a “neutral” rating and set a $3.16 price target on the stock. in a research report on Friday, May 1st. Piper Sandler downgraded Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, May 1st. Finally, Citizens Jmp lowered Esperion Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, May 1st. One analyst has rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Esperion Therapeutics currently has a consensus rating of “Hold” and an average price target of $5.54.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.

The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.